Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties II

ABSTRACT: Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties II

PROVIDER: PRJNA750798 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15300870.fastq.gz	Fastqsanger.gz
	SRR15300871.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties

Project description:Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties

| PRJNA750792 | ENA

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties III

Project description:Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties III

| PRJNA769684 | ENA

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties I

Project description:Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties I

| PRJNA750781 | ENA

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-12-21 | GSE181152 | GEO

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties I

Project description:This study reveals supeior efficiacy of triple combination treatment (TCT) based on anti-PD-(L)1 and anti-4-1BB/OX40 and describes immunological mechanisms underlying synergism between the treatment components

2021-12-21 | GSE181142 | GEO

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties III

2021-12-21 | GSE185566 | GEO

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties II

2021-12-21 | GSE181150 | GEO

Tumor-infiltrating CCR2+ inflammatory monocytes counteract specific immunotherapy

Project description:Tumor-infiltrating CCR2+ inflammatory monocytes counteract specific immunotherapy

| PRJNA1001913 | ENA

Single-cell RNA-seq of tumor-infiltrating lymphocytes in metastatic uveal melanoma

Project description:Metastatic uveal melanoma generally responds poorly to immunotherapy. The aim here was to sequence tumor-infiltrating lymphocytes from uveal melanoma metastases to study their phenotypes and T-cell receptor (TCR) clonotypes. We performed paired single-cell transcriptome and TCR sequencing using the 10x Genomics platform of IL2-expanded tumor-infiltrating lymphocytes from 7 liver and 1 subcutaneous metastasis.

2020-03-16 | E-MTAB-8846 | biostudies-arrayexpress

Multiplexed inhibition of immunosuppressive genes with Cas13d for on-demand combinatorial cancer immunotherapy

Project description:We devise Multiplex Universal Combinatorial Immunotherapy via Gene-silencing (MUCIG), as a versatile approach for combinatorial cancer immunotherapy. We harness CRISPR-Cas13d to efficiently target multiple endogenous immunosuppressive genes on demand, allowing us to silence various combinations of multiple immunosuppressive factors in the TME. Intra-tumoral AAV-mediated administration of MUCIG elicits significant anti-tumor activity with several Cas13d gRNA compositions (AAV-Cas13d-MUCIG). Optimization of TME targets by expression analysis led to a simplified off-the-shelf MUCIG targeting a four gene combination (PGGC: Pdl1/Cd274, Galectin9/Lgals9, Galectin3/Lgals3 and Cd47). AAV-Cas13d-PGGC showed significant in vivo anti-tumor efficacy in syngeneic tumor models. Single cell and flow profiling revealed that AAV-Cas13d-PGGC remodeled the TME by increasing CD8+ T cell infiltration and reducing neutrophils. MUCIG thus serves as a universal method to silence multiple immune genes in vivo, and can be delivered via AAV as a therapeutic approach. We devised an approach MUCIG (Multiplex Universal Combinatorial Immunotherapy via Gene-silencing) and designed MUCIG for targeting immunosuppressive genes at different scales of library pools. The first MUCIG pool included 313 genes selected based on these criteria. Subsequently, with a tiered approach, we designed three additional MUCIG pools (pool2: 152 genes; pool3: 55 genes; pool4: 19 genes). The distribution and coverage of gRNAs across all four pools were verified, confirming the robustness and specificity of this approach in the context of cancer immunosuppressive gene targeting therapy.

2024-12-05 | GSE269516 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data